Cyclocarya paliurus polysaccharides alleviate hyperuricemia in mice by regulating gut microbiota to enhance uric acid excretion.

Hyperuricemia, characterized by increased serum uric acid (SUA) levels, correlates with renal dysfunction and gut microbiota dysbiosis. Existing therapies often exhibit limited efficacy and adverse effects, highlighting the need for safe alternatives. This study aimed to evaluate the hypouricemic effects of Cyclocarya paliurus polysaccharides (CPP), and elucidate the gut microbiota-driven mechanisms by which CPP ameliorate hyperuricemia and renal inflammation. Results revealed that CPP alleviated hyperuricemia symptoms and mitigated renal inflammation. Additionally, CPP modulated gut microbiota by enhancing microbial diversity, enriching beneficial bacteria (e.g., Parabacteroides, Roseburia), and reducing pro-inflammatory bacteria (e.g., Lachnoclostridium_B). Metabolomics analysis further revealed CPP improved uric acid homeostasis and modulated key metabolic pathways associated with hyperuricemia. Correlation analysis of heat maps and validation experiments indicated the interplay between gut microbiota, uric acid excretion, and renal function. These findings demonstrate CPP alleviates hyperuricemia by restructuring gut microbiota and modulating metabolic pathways, highlighting it as a promising dietary supplement for managing hyperuricemia and its complications.